Search Results
Jul 29, 2026, 01:40 ET Seegene、グローバル・ミリオン臨床研究（GMCS）を通じて生殖器感染症の包括的な検査アプローチを提案
や性感染症（STI）など、生殖器の感染症を包括する疾患分類です。性感染症（STI）検査の対象分析項目クラミジア・トラコマティス (CT)、淋菌 (NG)、マイコプラズマ・ジェニタリウム (MG)、トリコモナス・ヴァギナリス (TV)、マイコプラズマ・ホミニス (MH)、ウレアプラズマ・ウレアリティカム (UU)、ウレアプラズマ・パルヴム (UP)、単純ヘルペスウイルス1型 (HSV-1)、単純ヘルペスウイルス2型 (HSV-2)、トレポネーマ・パリダム
More news about: Seegene Inc.
Jul 28, 2026, 14:32 ET Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
More news about: Glenmark Pharmaceuticals
Jul 28, 2026, 11:28 ET Lupin Announces the Approval of Diazepam Injection, USP in the United States
The U.S. FDA has approved Lupin's Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes as bioequivalent to the reference listed drug (RLD) Valium® Injection 10 mg/2 mL (5 mg/mL) of Hoffman-LaRoche, Inc. and is indicated for the management of anxiety disorders
More news about: Lupin Pharmaceuticals, Inc.
Jul 28, 2026, 08:00 ET PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent Protecting HemiClor® Formulation Technology
formulation technology incorporated into the first and only FDA-approved 12.5 mg chlorthalidone tablet through 2045, strengthening the intellectual property supporting HemiClor.HemiClor (chlorthalidone tablets, 12.5 mg) is indicated for the treatment of hypertension in adults to lower blood pressure.HemiClor
More news about: PRM Pharma, LLC
Jul 28, 2026, 02:00 ET Demand for EVs continues its growth across Europe with Chinese brands increasing market share, new OLX data shows
on technology and model choice as much as price, with Xpeng now among the leading brands alongside MG and BYD. Poland remains the group's most diversified Chinese brand market by brand count, with MG, BYD and Omoda leading. South Africa represents a different stage of market development. Chinese
More news about: OLX Group
Jul 28, 2026, 02:00 ET Demand for EVs continues its growth across Europe with Chinese brands increasing market share, new OLX data shows
on technology and model choice as much as price, with Xpeng now among the leading brands alongside MG and BYD. Poland remains the group's most diversified Chinese brand market by brand count, with MG, BYD and Omoda leading. South Africa represents a different stage of market development. Chinese
More news about: OLX Group
Jul 27, 2026, 09:35 ET OmniActive Introduces Fenavari
either a 300 mg or 500 mg dose saw improvements in menopause symptoms as early as day 14 of supplementation. At the end of the study, Fenavari demonstrated: Up to 52% reduction in hot flashes at 300 mg and up to 61% at 500 mg Up to 47% reduction in night sweats at 300 mg and up to
More news about: Fenavari
Jul 27, 2026, 09:00 ET CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
remaining attack-free during the 12-month treatment period. Participants aged 6 to 11 years (n = 16) received 100 mg of ANDEMBRY once monthly, while participants aged 2 to 5 years (n = 6) received 100 mg of ANDEMBRY every two months.ANDEMBRY is a monoclonal antibody that targets factor XIIa, a plasma protein
More news about: CSL
Jul 27, 2026, 09:00 ET GORGIE INTRODUCES CANDY APPLE, A NOSTALGIC NEW FLAVOR BRINGING A SWEET TWIST TO BETTER-FOR-YOU ENERGY
the category with better-for-you ingredients, functional benefits, and a community-driven approach where energy meets wellness. Each can features 150mg of green tea caffeine alongside wellness-supporting ingredients including Biotin, B Vitamins, and L-Theanine, delivering smooth, sustained energy without
More news about: GORGIE
Jul 27, 2026, 09:00 ET Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
(STIs).STI Test target analytesChlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), Herpes simplex
More news about: Seegene Inc.
Jul 27, 2026, 09:00 ET Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
(STIs).STI Test target analytesChlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), Herpes simplex
More news about: Seegene Inc.
Jul 27, 2026, 06:00 ET Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
moderate-to-severe AD who have received neither biologics targeting the same pathways as BBT001 nor JAK inhibitors were randomized 2:1 to receive either 450 mg IV of BBT001 or placebo once every two weeks during a four-week treatment period at clinical sites in New Zealand and the United States. This study's
More news about: Bambusa Therapeutics
Jul 26, 2026, 13:59 ET NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)
Arzneimittelagentur („EMA") eine positive Stellungnahme abgegeben hat, in der die Zulassung von Ubeslo® (Obicetrapib 10 mg als Monotherapie) und Evlarco® (10 mg Obicetrapib plus 10 mg Ezetimib als Fixdosiskombination („FDC")) für Patienten mit primärer Hypercholesterinämie, sowohl bei heterozygoter familiärer
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 25, 2026, 13:39 ET NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
favorable recommandant l'octroi d'une autorisation de mise sur le marché pour Ubeslo® (obicetrapib 10 mg en monothérapie) et Evlarco® (association à dose fixe (« FDC ») de 10 mg d'obicetrapib et de 10 mg d'ézétimibe) pour les patients atteints d'hypercholestérolémie primaire, qu'il s'agisse d'hypercholestérolémie
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 24, 2026, 17:25 ET American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter
2026 /PRNewswire/ -- American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass and/or paraformaldehyde.
More news about: American Regent, Inc.
Jul 24, 2026, 14:00 ET FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)
redefining what's possible in non-prescription pain management. TYLENOL® with Naproxen combines the fast-acting relief of 650 mg of acetaminophen with the long-lasting analgesic power of 220 mg naproxen sodium (a non-steroidal anti-inflammatory drug) in one dose, which begins working in under 30 minutes and provides
More news about: Kenvue Inc.
Jul 24, 2026, 12:57 ET NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo®
("EMA") ha emitido una opinión favorable recomendando la autorización de comercialización para Ubeslo® (obicetrapib 10 mg en monoterapia) y Evlarco® (obicetrapib 10 mg más ezetimiba 10 mg en combinación de dosis fija ("CDF")) para pacientes con hipercolesterolemia primaria, tanto familiar heterocigota ("HeFH")
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 24, 2026, 10:13 ET NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Medicines Agency ("EMA") has adopted a positive opinion recommending marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination ("FDC")) for patients with primary hypercholesterolemia, both heterozygous familial ("HeFH")
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 24, 2026, 09:00 ET ERAS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 08:30 ET Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
sexual-health testing with the cobas® CT/NG (Chlamydia trachomatis/Neisseria gonorrhoeae) and cobas® TV/MG (Trichomonas vaginalis/Mycoplasma genitalium) assays, eliminating the need for additional samples for extended testing.Roche's Sexual-Health
More news about: Roche
Jul 23, 2026, 11:58 ET Sunmed™ Endorses Bipartisan Lawful Hemp Protection Act to Protect Small Businesses and Consumer Access
standards that prioritize consumer safety. The bipartisan Bill will:Overturn Arbitrary Limits: Replace the job-killing 0.4 mg THC per container limit currently scheduled for November.Direct Scientific Review: Instruct the FDA to establish future
More news about: Sunmed
Jul 23, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
after market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed
More news about: Pomerantz LLP
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
patients with step-up dose 3 in the biweekly dosing schedule (N=153). CRS occurred in 30% of patients with the first 0.4 mg/kg treatment dose and in 12% of patients treated with the first 0.8 mg/kg treatment dose. The CRS rate for both dosing schedules combined was less than 3% for each of the remaining doses
More news about: Johnson & Johnson
Jul 23, 2026, 08:05 ET Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
alternatives.8OSVYRTI is available at a wholesaler acquisition cost (WAC) of $1,800.41 per 60 mg/mL single-dose pre-filled syringe, and JUBEREQ at a WAC price of $3,311.75 per 120 mg/1.7 mL (70 mg/mL) single-dose vial, supplying providers with more cost-efficient acquisition options for denosumab
More news about: Accord BioPharma
Jul 23, 2026, 07:29 ET Ribo publie des résultats positifs suite à l'essai de Phase 2a réalisé sur le vortosiran - Premières données cliniques au monde sur l'inhibition du facteur XI par pARNi après administration de plusieurs doses chez des patients atteints de coronaropathie
myocarde et sous traitement à l'aspirine. Les patients ayant suivi le schéma posologique à forte dose de vortosiran, à raison d'une dose d'entretien de 400 mg, ont obtenu une réduction maximale moyenne de l'activité du facteur XI de 92 %, qui s'est maintenue pendant plusieurs mois après l'administration. Ces
More news about: Suzhou Ribo Life Science Co., Ltd.